HAMILTON, Bermuda, June 25, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical needs, announced today that the underwriters of its initial public offering exercised their option to purchase an additional 1,006,425 Class A common shares at the public offering price of $18.00 per share, less underwriting discounts and commissions. After giving effect to the exercise of the underwriters’ option to purchase additional shares, Kiniksa has sold a total of 9,484,202 Class A common shares in its initial public offering, for total gross proceeds of approximately $170.7 million, before deducting underwriting discounts and commissions and offering expenses.
Kiniksa’s Class A common shares began trading on the Nasdaq Global Select Market on May 24, 2018 under the ticker symbol “KNSA.”
Goldman Sachs & Co. LLC and J.P. Morgan Securities, LLC acted as joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. acted as co-managers for the offering.
A registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission. The offering of these securities was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained by contacting: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com; or from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: 1-866-803-9204, or via email at prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kiniksa
Kiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions.
Every Second Counts!™
Kiniksa Investor and Media Contact
Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com